seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases

Hanover, Germany, October 14, 2026 – seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding...